WuXi Biologics Achieves "CDMO of the Year" Among Three Prestigious IMAPAC Awards
WuXi Biologics (OTC:WXXWY) has secured three prestigious awards at the Asia Pacific Biologics CDMO Excellence Awards 2025, including "CDMO of the Year – Asia Pacific". The company's achievements include managing 864 integrated projects, comprising 168 bispecific/multispecific antibodies and 225 ADCs, while maintaining a 100% success rate in Pre-License Inspections.
The company has demonstrated exceptional efficiency by reducing monoclonal antibody development cycles to 6 months from DNA to IND. WuXi Biologics has successfully passed 44 global regulatory inspections, including 22 from FDA and EMA, while serving over 1,000 clients globally with end-to-end biologics services.
WuXi Biologics (OTC:WXXWY) ha ottenuto tre prestigiosi premi agli Asia Pacific Biologics CDMO Excellence Awards 2025, tra cui "CDMO dell'Anno – Asia Pacific". I traguardi dell'azienda includono la gestione di 864 progetti integrati, comprendenti 168 anticorpi bispecifici/multispecifici e 225 ADC, mantenendo un tasso di successo del 100% nelle ispezioni pre-licenza. L'azienda ha dimostrato un'efficienza eccezionale riducendo i cicli di sviluppo degli anticorpi monoclonali a 6 mesi dal DNA all'IND. WuXi Biologics ha superato con successo 44 ispezioni regolatorie globali, tra cui 22 dalla FDA e EMA, servendo oltre 1.000 clienti globali con servizi biologici end-to-end.
WuXi Biologics (OTC:WXXWY) ha obtenido tres prestigiosos premios en los Asia Pacific Biologics CDMO Excellence Awards 2025, incluyendo "CDMO del Año – Asia Pacífico". Entre los logros se destacan la gestión de 864 proyectos integrados, que comprenden 168 anticuerpos bispecíficos/multipecíficos y 225 ADC, manteniendo una tasa de éxito del 100% en las inspecciones de pre-licencia. La empresa ha mostrado una eficiencia excepcional al reducir los ciclos de desarrollo de anticuerpos monoclonales a 6 meses desde el ADN hasta el IND. WuXi Biologics ha superado con éxito 44 inspecciones regulatorias globales, incluidas 22 de la FDA y la EMA, atendiendo a más de 1,000 clientes globales con servicios biológicos de extremo a extremo.
WuXi Biologics (OTC:WXXWY)은 Asia Pacific Biologics CDMO Excellence Awards 2025에서 아시아 태평양 CDMO 올해의 상를 포함해 세 가지 명예로운 상을 수상했습니다. 864개의 통합 프로젝트를 관리했고 그 중 168개의 이중/다중 특이 항체와 225개의 ADC를 포함하며, 사전승인 검사에서 100% 성공을 유지했습니다. 또한 DNA에서 IND까지 항체 단클론 개발 주기를 6개월로 단축하는 등 탁월한 효율성을 입증했습니다. FDA 및 EMA를 포함한 44건의 글로벌 규제 검사를 성공적으로 통과했으며, 전 세계적으로 1,000개 이상의 고객에게 엔드투엔드 생물의약 서비스를 제공하고 있습니다.
WuXi Biologics (OTC:WXXWY) a remporté trois prix prestigieux lors des Asia Pacific Biologics CDMO Excellence Awards 2025, y compris le CDMO de l'année – Asie-Pacifique. Parmi les réalisations figurent la gestion de 864 projets intégrés, comprenant 168 anticorps bispécifiques/multi-spécifiques et 225 ADC, tout en maintenant un taux de réussite de 100% lors des inspections pré-licence. L'entreprise a démontré une efficacité exceptionnelle en réduisant les cycles de développement des anticorps monoclonaux à 6 mois du ADN à l'IND. WuXi Biologics a réussi 44 inspections réglementaires mondiales, dont 22 de la FDA et de l'EMA, tout en desservant plus de 1 000 clients dans le monde avec des services biologiques de bout en bout.
WuXi Biologics (OTC:WXXWY) hat bei den Asia Pacific Biologics CDMO Excellence Awards 2025 drei renommierte Auszeichnungen erhalten, darunter "CDMO des Jahres – Asia Pacific". Zu den Leistungen gehören die Verwaltung von 864 integrierten Projekten, darunter 168 Bispezifische/Multispezifische Antikörper und 225 ADCs, bei einer 100%-igen Erfolgsquote in Pre-License Inspections. Das Unternehmen hat durch die Verkürzung der Entwicklungskreisläufe für monoklonale Antikörper von DNA bis IND auf 6 Monate herausragende Effizienz gezeigt. WuXi Biologics hat 44 globale regulatorische Inspektionen erfolgreich bestanden, darunter 22 von FDA und EMA, und bedient weltweit über 1.000 Kunden mit End-to-End-Biologics-Services.
أعلنت WuXi Biologics (OTC:WXXWY) عن فوزها بثلاث جوائز مرموقة في جوائز التميّز CDMO للبيولوجيا بمنطقة آسيا والمحيط الهادئ 2025، من بينها CDMO للسنة – آسيا والمحيط الهادئ. تشمل الإنجازات إدارة 864 مشروعاً متكاملاً، منها 168 جسماً مضاداً ثنائي/متعدد الخصائص و225 ADC، مع الحفاظ على معدل نجاح 100% في فحوصات ما قبل الترخيص. أظهرت الشركة كفاءة استثنائية عبر تقليل دورات تطوير الأجسام المضادة أحادية النسيلة إلى 6 أشهر من الـDNA إلى IND. نجحت WuXi Biologics بعبور 44 تفتيشاً تنظيمياً عالمياً، بما في ذلك 22 من FDA وEMA، مع خدمة أكثر من ألف عميل عالمي بمدى بيولوجي متكامل من البداية للنهاية.
WuXi Biologics (OTC:WXXWY) 在亚洲太平洋生物制药CDMO卓越奖2025中获得三项知名奖项，其中包括“亚太区年度CDMO”。公司成就包括管理< b>864个综合项目，其中包含< b>168种双特异/多特异抗体和< b>225种ADC，在< b>预许可检查中保持< b>100%的合格率。公司通过将单克隆抗体开发周期从DNA到IND缩短至< b>6个月，展现出卓越的效率。WuXi Biologics已成功通过< b>44项全球监管检查，其中包含< b>来自FDA和EMA的22项，并为全球超过< b>1,000家客户提供端到端生物制药服务。
- Portfolio of 864 integrated projects, including 168 bispecific antibodies and 225 ADCs
- 100% success rate in Pre-License Inspections (PLI)
- Passed 44 global regulatory inspections, including 22 from FDA and EMA
- Reduced monoclonal antibody development cycle to 6 months
- Serves over 1,000 global clients with end-to-end biologics services
- None.
APBCEA aims to celebrate the outstanding contributions of leading CDMO that are accelerating biologics innovation across
WuXi Biologics is committed to advancing integrated technology platforms to accelerate the discovery, development, and manufacturing of biologics. It boasts one of the industry's largest portfolios of complex biologics, with total integrated projects reaching 864, including 168 bispecific and multispecific antibodies and 225 ADCs. The development cycle for its monoclonal antibody projects, from DNA to Investigational New Drug (IND) application, has been shortened to 6 months, demonstrating high flexibility. Behind these milestone achievements lies the solid support of the company's world-class quality systems—which have achieved a
Dr. Chris Chen, CEO of WuXi Biologics, commented, "We are very pleased that WuXi Biologics has once again won multiple awards presented by IMAPAC, which fully demonstrates the recognition we have earned from both clients and the industry for the value we consistently deliver. Through unremitting efforts in pursuing excellence, adherence to world-class quality standards, a visionary leadership team, and the dedicated global team, we remain steadfast in empowering our partners to accelerate groundbreaking therapies to patients worldwide at an earlier date."
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in
WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts, and promote responsible practices that empower the entire value chain.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com
Contacts
Business
info@wuxibiologics.com
Media
PR@wuxibiologics.com
View original content:https://www.prnewswire.com/news-releases/wuxi-biologics-achieves-cdmo-of-the-year-among-three-prestigious-imapac-awards-302554582.html
SOURCE WuXi Biologics
FAQ
What awards did WuXi Biologics (WXXWY) win at IMAPAC 2025?
How many integrated projects does WuXi Biologics currently manage?
What is WuXi Biologics' success rate in regulatory inspections?
How long does WuXi Biologics take to develop monoclonal antibodies from DNA to IND?
How many clients does WuXi Biologics serve worldwide?
